|
Market Closed -
OTC Markets
15:27:19 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 235.44 USD | -1.30% |
|
-4.34% | -19.80% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
UCB(UCB)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
UCB(UCB)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
- Stock Market
- Stocks
- UCB Stock
- UCBJF Stock
- Consensus UCB
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
